| Literature DB >> 35370977 |
Xiaoting Zhou1,2,3, Xiaomei Wu1,2,3, Xi Luo1,2,3,4, Jingyi Shao1,2, Dongqun Guo5, Bo Deng1,2, Ze Wu1,2.
Abstract
Despite numerous studies indicating an imperative role of vitamin D for reproduction, the importance of vitamin D supplementation on in vitro fertilization (IVF) outcomes remains controversial. We therefore performed this meta-analysis to investigate the IVF outcomes of vitamin D supplementation in infertile women with vitamin D deficiency. We systematically searched PubMed, Embase and the Cochrane library for identifying all relevant studies published before August 2021. Pregnancy rate was defined as the primary outcome while good quality embryo, fertilization rate, ongoing pregnancy, and miscarriage were secondary outcomes. We used Review Manager 5.3 (RevMan) to conduct meta-analysis and examined the robustness of the primary outcome by trial sequential analysis. Five studies were included in the final analysis and it suggested that vitamin D supplementation was associated with improved chemical pregnancy rate (risk ratio [RR] = 1.53, 95% confidence interval [CI] = 1.06 to 2.20, p = 0.02) but not benefited in improving clinical pregnancy rate (RR = 1.34, 95% CI = 0.81 to 2.24, p = 0.25) and all secondary outcomes. Trial sequential analysis suggested further studies are needed to confirm this conclusion. We concluded that vitamin D supplementation should be prescribed to improve chemical pregnancy in infertile women with vitamin D deficiency and more studies are required to further confirm this finding.Entities:
Keywords: in vitro fertilization; meta-analysis; trial sequential analysis; vitamin D deficiency; vitamin D supplementation
Mesh:
Substances:
Year: 2022 PMID: 35370977 PMCID: PMC8969598 DOI: 10.3389/fendo.2022.852428
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Figure 1Flow diagram of searching and selecting eligible study in this meta-analysis.
Basic characteristics of 5 eligible studies.
| Study | Country | Sample size | Age, yrs | BMI, kg/m2 | Pretreatment serum vitamin D, (ng/ml) | Details of regimes |
|---|---|---|---|---|---|---|
| Aflatoonian et al. ( | Iran | 51 vs 55 | (28.45 ± 3.74) vs (29.56 ± 4.68) | (26.87 ± 1.77) vs (26.29 ± 1.67) | (15.81 ± 5.94) vs (14.2 ± 6.33) | 50,000 IU vitamin D pearl capsule weekly, for 6-8 weeks |
| Abedi et al. ( | Iran | 42 vs 43 | (31.9 ± 4.2) vs (30.8 ± 4.4) | (23.9 ± 2.1) vs (23.8 ± 1.9) | n.r. | 50,000 IU vitamin D pearl capsule weekly, for 6 weeks |
| Bezerra Espinola et al. ( | Italy | 50 vs 50 | (34.7 ± 6.7) vs (35.9 ± 3.7) | (21.9 ± 2.1) vs (22.0 ± 2.3) | (23.4 ± 6.7) vs (23.4 ± 6.6) | 2,000 IU vitamin D3 for 12 weeks |
| Doryanizadeh, et al. ( | Iran | 36 vs 38 | (32.5 ± 4.9) vs (31.6 ± 4.9) | (25.3 ± 3.2) vs (24.9 ± 3.4) | (27.5 ± 1.8) vs (27.6 ± 1.8) | 0.25 µg calcitriol pills daily for 4 weeks |
| Somigliana et al. ( | Italy | 285 vs 288 | (35.0 [32.0–37.0]) vs (35.0 [33.0–37.0]) | (20.8 [19.5–22.5]) vs (21.1 [19.7–22.9]) | (20.0 [15.5–23.6]) vs (19.9 [14.6–23.9]) | single dose of 600,000 IU of vitamin D3 |
yrs, years; CMP, chemical pregnancy; CNP, clinical pregnancy; FR, fertilization rate; GQE, good quality embryo; n.r., not reported.
Figure 2Risk of bias summary of eligible studies.
Figure 3Meta-analysis of pregnancy rate between vitamin D supplementation and no supplementation.
Figure 4Trial sequential analysis of chemical and clinical pregnancy. (A) Required sample size of 462; (B) required sample size of 1570.
Figure 5Meta-analysis of secondary outcomes, namely, good quality embryo (A), fertilization rate (B), ongoing pregnancy (C), and miscarriage (D).